Prulifloxacin Tablets
Function and Efficacy
This product belongs to the quinolone antibiotics. It inhibits the activity of bacterial DNA topoisomerase II and IV, inhibits bacterial DNA synthesis, and completes the bactericidal effect. It is different from the traditional bactericidal mode and does not have the drug resistance phenomenon of other antibiotics. This drug has a broad antibacterial spectrum and has significant therapeutic effects on both Gram-negative and Gram-positive bacteria. It is particularly sensitive to Pseudomonas aeruginosa, and its antibacterial power exceeds that of other oxazolidinones and other currently marketed antibiotics.
Ingredients
The main ingredient of this product is prulifloxacin, and its chemical name is: (±)-6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolane)methyl-1-piperazine]-4-oxo-4H-[1,3]thiazolyl[3,2-a]quinoline-3-carboxylic acid
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| PrulifloxacinIngredients |
This product belongs to the quinolone antibiotics. It inhibits the activity of bacterial DNA topoisomerase II and IV, inhibits bacterial DNA synthesis, and completes the bactericidal effect. It is different from the traditional bactericidal mode and does not have the drug resistance phenomenon of other antibiotics. This drug has a broad antibacterial spectrum and has significant therapeutic effects on both Gram-negative and Gram-positive bacteria. It is particularly sensitive to Pseudomonas aeruginosa, and its antibacterial power exceeds that of other oxazolidinones and other currently marketed antibiotics. More |
123447-62-1 | 14 |
Appearance
This product is a film-coated tablet, which appears light yellow or yellow after removing the coating.
Indication
It is used to treat the following infections caused by Staphylococci, gonococci, pneumococci, enterococci, Moraxella, Escherichia coli, Shigella, Salmonella (except typhoid and paratyphoid bacteria), citric acid bacteria, Klebsiella pneumoniae, Serratia, Proteus, Vibrio cholerae, Pseudomonas aeruginosa, and Streptococcus aureus that are sensitive to prulifloxacin: (1) superficial skin infections (acute superficial folliculitis, infectious impurities), deep skin infections (cellulitis, erysipelas, furunculosis, furunculosis, carbuncle, suppurative perionychia), chronic pyoderma (infected sebaceous cysts, suppuration, etc.).
Usage and Dosage
Oral administration. Usually adults take 0.2g at a time, twice a day. The dosage can be adjusted appropriately according to symptoms, but the dosage should not exceed 0.3g at a time. For patients with secondary infections of pneumonia and chronic respiratory diseases, take 0.3g at a time, twice a day.
Adverse Reactions
Eosinopenia and elevated liver GPT were mild.
Precautions
Not yet clear
Special Population Medication
Precautions for children: Do not use this product because its safety has not been established for low-birth-weight infants, newborns, nursing infants, infants and children. Precautions for pregnancy and lactation: The safety of this product for pregnant and lactating women has not been established. Lactating women should stop breastfeeding when taking this product. Precautions for the elderly: The half-life of this product is prolonged after the elderly take it.
Drug Interactions
Not yet clear
Storage
seal
Packaging Specification
0.1g (calculated as C16H16FN3O3S)
Validity Period
24 months
Manufacturer
Jiangsu Kanion Pharmaceutical Co., Ltd.
-
Founded in:
1996-05-08 -
Address:
Lianyungang Economic and Technological Development Zone Jiangning Industrial City -
Tax NO.:
91320700138997640W -
Registered Funds:
581.797452 million yuan -
Website:
-
Email: